Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis

BACKGROUND: Epithelial sodium channel (ENaC) is an important regulator of airway surface liquid volume; ENaC is hyperactivated in cystic fibrosis (CF). ENaC inhibition is a potential therapeutic target for CF. Here, we report in vitro and in vivo results for BI 1265162, an inhaled ENaC inhibitor cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickolaus, Peter, Jung, Birgit, Sabater, Juan, Constant, Samuel, Gupta, Abhya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720687/
https://www.ncbi.nlm.nih.gov/pubmed/33313305
http://dx.doi.org/10.1183/23120541.00429-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720687/
https://www.ncbi.nlm.nih.gov/pubmed/33313305
http://dx.doi.org/10.1183/23120541.00429-2020

Ejemplares similares